Literature DB >> 26889237

Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease.

Weihan Zhao1, Lijuan Liu1, Yunliang Wang1, Tangyou Mao1, Junxiang Li1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a prevalent disease, with a clinical spectrum ranging from simple fatty liver disease to nonalcoholic steatohepatitis and cirrhosis. Puerarin, baicalin and berberine are herbal products widely used in Asia, which are believed to possess therapeutic benefits for alleviating the symptoms of NAFLD. In the present study, a rat model of NAFLD, induced by a high-fat diet, was established and orthographical experimentation was used to investigate the effects of various combinations of puerarin, baicalin and berberine on the hepatic expression of proliferator-activated receptor (PPAR)-γ and insulin receptor (IR). The present study demonstrated that serum levels of total cholesterol, alanine transaminase and low-density lipoproteins were significantly decreased in the puerarin-dominated groups (P<0.05 vs. the model group), whereas the concentrations of tumor necrosis factor-α and interleukin-6 were significantly improved in the baicalin- and berberine-dominated groups (P<0.05 vs. the model group). Furthermore, as compared with the control group, the levels of PPAR-γ/IR mRNA and protein expression were significantly decreased in the model group (P<0.01), and significantly increased in the rosiglitazone group and some of the orthogonal experiment groups (P<0.01). In conclusion, a combination of puerarin, baicalin and berberine induced favorable effects on NAFLD by upregulating hepatic PPAR-γ and IR expression levels, and different proportions of monomer compositions exerted variable positive effects on various stages of NAFLD.

Entities:  

Keywords:  baicalin; berberine; insulin receptor; non-alcoholic fatty liver disease; proliferator-activated receptor-γ; puerarin

Year:  2015        PMID: 26889237      PMCID: PMC4726904          DOI: 10.3892/etm.2015.2846

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  37 in total

Review 1.  Complementary and alternative medicine in chronic liver disease.

Authors:  L B Seeff; K L Lindsay; B R Bacon; T F Kresina; J H Hoofnagle
Journal:  Hepatology       Date:  2001-09       Impact factor: 17.425

2.  Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution?

Authors:  Stephen A Harrison
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

3.  Cysteine 647 in the insulin receptor is required for normal covalent interaction between alpha- and beta-subunits and signal transduction.

Authors:  B Cheatham; C R Kahn
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

4.  Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.

Authors:  XinXia Chang; HongMei Yan; Jing Fei; MingHong Jiang; HongGuang Zhu; DaRu Lu; Xin Gao
Journal:  J Lipid Res       Date:  2010-06-21       Impact factor: 5.922

5.  Chrysin and luteolin alleviate vascular complications associated with insulin resistance mainly through PPAR-γ activation.

Authors:  Hany M El-Bassossy; Shaymaa M Abo-Warda; Ahmed Fahmy
Journal:  Am J Chin Med       Date:  2014-08-29       Impact factor: 4.667

6.  Chromium-containing traditional Chinese medicine, Tianmai Xiaoke Tablet improves blood glucose through activating insulin-signaling pathway and inhibiting PTP1B and PCK2 in diabetic rats.

Authors:  Qian Zhang; Xin-Hua Xiao; Ming Li; Wen-Hui Li; Miao Yu; Hua-Bing Zhang; Fan Ping; Zhi-Xin Wang; Jia Zheng
Journal:  J Integr Med       Date:  2014-05

Review 7.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

Review 8.  Metabolic syndrome and NASH.

Authors:  Giulio Marchesini; Rebecca Marzocchi
Journal:  Clin Liver Dis       Date:  2007-02       Impact factor: 6.126

9.  Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice.

Authors:  Bilal Haider Shamsi; Chaofeng Ma; Saima Naqvi; Yanfeng Xiao
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

10.  Effect of physical training on liver expression of activin A and follistatin in a nonalcoholic fatty liver disease model in rats.

Authors:  R N Silva; P G Bueno; L R S Avó; K O Nonaka; H S Selistre-Araújo; A M O Leal
Journal:  Braz J Med Biol Res       Date:  2014-07-25       Impact factor: 2.590

View more
  11 in total

1.  Baicalin and its aglycone: a novel approach for treatment of metabolic disorders.

Authors:  Penghua Fang; Mei Yu; Mingyi Shi; Ping Bo; Xuewen Gu; Zhenwen Zhang
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 2.  Nuclear receptors and nonalcoholic fatty liver disease.

Authors:  Matthew C Cave; Heather B Clair; Josiah E Hardesty; K Cameron Falkner; Wenke Feng; Barbara J Clark; Jennifer Sidey; Hongxue Shi; Bashar A Aqel; Craig J McClain; Russell A Prough
Journal:  Biochim Biophys Acta       Date:  2016-03-04

3.  Antitumor effects of baicalin on ovarian cancer cells through induction of cell apoptosis and inhibition of cell migration in vitro.

Authors:  Chen Gao; Yinglu Zhou; Huatao Li; Xia Cong; Zhongling Jiang; Xin Wang; Rongfeng Cao; Wenru Tian
Journal:  Mol Med Rep       Date:  2017-10-10       Impact factor: 2.952

Review 4.  Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.

Authors:  Inés Mármol; Cristina Sánchez-de-Diego; Alberto Pradilla Dieste; Elena Cerrada; María Jesús Rodriguez Yoldi
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 5.923

5.  Upregulation of UDP-Glucuronosyltransferases 1a1 and 1a7 Are Involved in Altered Puerarin Pharmacokinetics in Type II Diabetic Rats.

Authors:  Songtao Dong; Maofan Zhang; Huimin Niu; Kunyu Jiang; Jialei Jiang; Yinglin Ma; Xin Wang; Shengnan Meng
Journal:  Molecules       Date:  2018-06-20       Impact factor: 4.411

6.  Effect of Puerarin Regulated mTOR Signaling Pathway in Experimental Liver Injury.

Authors:  Bu-Gao Zhou; Hai-Mei Zhao; Xiu-Yun Lu; Wen Zhou; Fu-Chun Liu; Xue-Ke Liu; Duan-Yong Liu
Journal:  Front Pharmacol       Date:  2018-10-23       Impact factor: 5.810

7.  Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARα expression in rats with chronic heart failure.

Authors:  Le He; Tong Wang; Bing-Wei Chen; Feng-Min Lu; Jing Xu
Journal:  Exp Ther Med       Date:  2019-09-06       Impact factor: 2.447

Review 8.  Protective effect of isoflavones and triterpenoid saponins from pueraria lobata on liver diseases: A review.

Authors:  Heng He; Shuwei Peng; Xu Song; Renyong Jia; Yuanfeng Zou; Lixia Li; Zhongqiong Yin
Journal:  Food Sci Nutr       Date:  2021-12-10       Impact factor: 2.863

Review 9.  Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: A review.

Authors:  Risha Ganguly; Ashutosh Gupta; Abhay K Pandey
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

10.  Baicalin Attenuates Oxidative Stress in a Tissue-Engineered Liver Model of NAFLD by Scavenging Reactive Oxygen Species.

Authors:  Wen Gao; Bin Xu; Yizhi Zhang; Shuang Liu; Zhongping Duan; Yu Chen; Xiaohui Zhang
Journal:  Nutrients       Date:  2022-01-26       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.